Published in Gynecol Oncol on December 14, 2009
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 1.32
Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer (2012) 1.01
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer (2010) 0.95
Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One (2014) 0.92
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol (2013) 0.91
Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One (2013) 0.89
The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells. EMBO Rep (2012) 0.87
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch (2011) 0.86
The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol (2013) 0.86
Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85
Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors. Cell Biosci (2015) 0.80
Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. Oncogene (2016) 0.78
Epithelial ovarian cancer inherent resistance: May the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecol Oncol Rep (2016) 0.77
The role of B cells in transplantation and immunopathic diseases. Immune Netw (2010) 0.75
Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer. BMC Cancer (2014) 0.75
Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma. J Gynecol Oncol (2010) 0.75
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ Health Perspect (2012) 4.89
Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol (2004) 4.59
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol (2005) 3.31
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med (2009) 2.60
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol (2007) 2.25
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstet Gynecol (2015) 2.02
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Identification of the single base change causing the callipyge muscle hypertrophy phenotype, the only known example of polar overdominance in mammals. Genome Res (2002) 1.91
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90
Role of premature leptin surge in obesity resulting from intrauterine undernutrition. Cell Metab (2005) 1.83
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) (2009) 1.78
Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply. Arch Pathol Lab Med (2013) 1.78
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res (2006) 1.74
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (2005) 1.71
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol (2008) 1.65
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy. Epigenetics (2011) 1.60
Unfolded protein response genes regulated by CED-1 are required for Caenorhabditis elegans innate immunity. Dev Cell (2008) 1.59
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res (2008) 1.57
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer (2003) 1.56
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol (2003) 1.55
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res (2003) 1.54
Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod (2007) 1.53
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Hum Mol Genet (2013) 1.52
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.49
Ovarian cancer risk factors in African-American and white women. Am J Epidemiol (2009) 1.49
Evaluation of two management strategies for preoperative grade 1 endometrial cancer. Obstet Gynecol (2009) 1.48
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet (2010) 1.47
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol (2008) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Paternal obesity is associated with IGF2 hypomethylation in newborns: results from a Newborn Epigenetics Study (NEST) cohort. BMC Med (2013) 1.44
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer. Gynecol Oncol (2011) 1.44
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res (2006) 1.43
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet (2009) 1.42
Failure of terminal erythroid differentiation in EKLF-deficient mice is associated with cell cycle perturbation and reduced expression of E2F2. Mol Cell Biol (2008) 1.42
Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis. Leuk Res (2004) 1.41
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol Oncol (2004) 1.41
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Cervical clamp with ring forceps to prevent prolapse of an intrauterine balloon in the management of postpartum hemorrhage. J Obstet Gynaecol Res (2012) 1.39
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother (2008) 1.38
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36